1. Home
  2. IFRX

IFRX

InflaRx N.V.

Logo InflaRx N.V.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Founded: 2007 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 89.5M IPO Year: 2017
Target Price: $13.50 AVG Volume (30 days): 223.8K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.83 EPS Growth: N/A
52 Week Low/High: $1.14 - $5.20 Next Earning Date: 05-09-2024
Revenue: $70,099 Revenue Growth: N/A
Revenue Growth (this year): 7127.88% Revenue Growth (next year): 59.54%

Share on Social Networks: